The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis

INTRODUCTION: The biosimilar product Inflectra(®) has been approved by the European Medicine Agency (EMA) for the same indications as its reference drug, infliximab, based on studies in patients with rheumatic diseases. Thus far, there have not been enough data regarding its efficacy and safety in u...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaniewska, Magdalena, Moniuszko, Andrzej, Rydzewska, Grażyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672704/
https://www.ncbi.nlm.nih.gov/pubmed/29123576
http://dx.doi.org/10.5114/pg.2017.70468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672704/
https://www.ncbi.nlm.nih.gov/pubmed/29123576
http://dx.doi.org/10.5114/pg.2017.70468

Ejemplares similares